Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SHR3680 versus bicalutamide in hormone-sensitive prostate cancer
CTR20180560Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezvilutamide in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Jun 2018; status: active.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20180560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180560.